Puma Biotechnology Inc (PBYI): Price and Financial Metrics


Puma Biotechnology Inc (PBYI): $7.30

0.18 (+2.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PBYI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

PBYI POWR Grades


  • Value is the dimension where PBYI ranks best; there it ranks ahead of 94.83% of US stocks.
  • PBYI's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • PBYI ranks lowest in Momentum; there it ranks in the 9th percentile.

PBYI Stock Summary

  • Puma Biotechnology Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 96.3% of US listed stocks.
  • The price/operating cash flow metric for Puma Biotechnology Inc is higher than 76.19% of stocks in our set with a positive cash flow.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 25.94 for Puma Biotechnology Inc; that's greater than it is for 98.37% of US stocks.
  • Stocks that are quantitatively similar to PBYI, based on their financial statements, market capitalization, and price volatility, are QTWO, MANH, NSTG, AERI, and LPSN.
  • Visit PBYI's SEC page to see the company's official filings. To visit the company's web site, go to www.pumabiotechnology.com.

PBYI Valuation Summary

  • PBYI's EV/EBIT ratio is -16.1; this is 154.95% lower than that of the median Healthcare stock.
  • Over the past 114 months, PBYI's EV/EBIT ratio has gone up 6.
  • PBYI's price/sales ratio has moved NA NA over the prior 114 months.

Below are key valuation metrics over time for PBYI.

Stock Date P/S P/B P/E EV/EBIT
PBYI 2021-08-31 1.2 10.5 -8.8 -16.1
PBYI 2021-08-30 1.2 10.5 -8.9 -16.2
PBYI 2021-08-27 1.2 10.6 -8.9 -16.3
PBYI 2021-08-26 1.2 10.1 -8.5 -15.6
PBYI 2021-08-25 1.2 10.4 -8.7 -15.9
PBYI 2021-08-24 1.2 10.3 -8.6 -15.8

PBYI Growth Metrics

  • The 4 year cash and equivalents growth rate now stands at 11.76%.
  • The 2 year revenue growth rate now stands at 138.22%.
  • Its year over year price growth rate is now at -2.02%.
PBYI's revenue has moved up $254,864,000 over the prior 70 months.

The table below shows PBYI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 254.864 11.672 -35.035
2021-03-31 272.062 27.974 -26.534
2020-12-31 225.11 0.773 -59.995
2020-09-30 235.475 7.974 -56.2
2020-06-30 241.073 -1.053 -41.622
2020-03-31 224.41 26.966 -82.441

PBYI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PBYI has a Quality Grade of C, ranking ahead of 65.48% of graded US stocks.
  • PBYI's asset turnover comes in at 0.995 -- ranking 23rd of 677 Pharmaceutical Products stocks.
  • SRNE, VBLT, and XOMA are the stocks whose asset turnover ratios are most correlated with PBYI.

The table below shows PBYI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.995 0.755 -0.266
2021-03-31 1.058 0.780 -0.137
2020-12-31 0.905 0.825 -0.449
2020-09-30 0.955 0.836 -0.355
2020-06-30 1.008 0.842 -0.212
2020-03-31 0.963 0.831 -0.448

PBYI Price Target

For more insight on analysts targets of PBYI, see our PBYI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.63 Average Broker Recommendation 2.17 (Hold)

PBYI Stock Price Chart Interactive Chart >

Price chart for PBYI

PBYI Price/Volume Stats

Current price $7.30 52-week high $14.14
Prev. close $7.12 52-week low $6.48
Day low $7.23 Volume 639,600
Day high $7.73 Avg. volume 371,823
50-day MA $7.29 Dividend yield N/A
200-day MA $9.69 Market Cap 297.69M

Puma Biotechnology Inc (PBYI) Company Bio


Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.


PBYI Latest News Stream


Event/Time News Detail
Loading, please wait...

PBYI Latest Social Stream


Loading social stream, please wait...

View Full PBYI Social Stream

Latest PBYI News From Around the Web

Below are the latest news stories about Puma Biotechnology Inc that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference

LOS ANGELES, September 21, 2021--Alan Auerbach will present an overview of Puma Biotechnology at 8:00 a.m. EDT on Sept. 28, at the 2021 Cantor Virtual Global Healthcare Conference.

Yahoo | September 21, 2021

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--On Sept. 7, 2021, Puma Biotechnology reported inducement awards granted to new staff in August, as required by Nasdaq Listing Rule 5635(c)(4) .

Business Wire | September 7, 2021

Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at the H.C. Wainwright 23rd Annual Global Investment Conference beginning on Sept. 13.

Business Wire | September 7, 2021

Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut

Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.

Yahoo | August 6, 2021

Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 58.06% and 4.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 6, 2021

Read More 'PBYI' Stories Here

PBYI Price Returns

1-mo -4.70%
3-mo -20.48%
6-mo -26.71%
1-year -27.22%
3-year -84.08%
5-year -88.95%
YTD -28.85%
2020 17.26%
2019 -57.00%
2018 -79.41%
2017 221.99%
2016 -60.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0166 seconds.